Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Retained Earnings (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Retained Earnings for 5 consecutive years, with -$426.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Retained Earnings fell 8.37% to -$426.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$426.8 million, a 8.37% decrease, with the full-year FY2024 number at -$404.8 million, down 1226736.36% from a year prior.
  • Retained Earnings was -$426.8 million for Q3 2025 at Lyra Therapeutics, down from -$420.8 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $33000.0 in Q4 2023 to a low of -$426.8 million in Q3 2025.
  • A 5-year average of -$232.4 million and a median of -$219.7 million in 2022 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: surged 230.0% in 2023, then plummeted 5625771.43% in 2024.
  • Lyra Therapeutics' Retained Earnings stood at -$193.4 million in 2021, then skyrocketed by 100.01% to $10000.0 in 2022, then soared by 230.0% to $33000.0 in 2023, then tumbled by 1226736.36% to -$404.8 million in 2024, then dropped by 5.43% to -$426.8 million in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Retained Earnings are -$426.8 million (Q3 2025), -$420.8 million (Q2 2025), and -$413.3 million (Q1 2025).